KDR and non-small cell lung carcinoma: In the same year, nintedanib, an oral medication that can simultaneously inhibit triple angiokinase, VEGFR, platelet-derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR) signalling pathways, was approved to be used in combination with docetaxel in patients with locally advanced, metastatic, or locally recurrent NSCLC adenocarcinoma, after first-line chemotherapy [37].